Suppr超能文献

心脏移植中的诱导治疗:时机与原因?

Induction therapy in cardiac transplantation: when and why?

作者信息

Baran David A

机构信息

Newark Beth Israel Medical Center, Newark, NJ 07112, USA.

出版信息

Heart Fail Clin. 2007 Jan;3(1):31-41. doi: 10.1016/j.hfc.2007.02.009.

Abstract

Induction therapy has continued to be a subject of controversy in heart transplantation for more than 20 years. It is an example of a therapy that is logical, and ought to be better than "doing without." However, a careful review of the evidence suggests otherwise. Except for patients where the benefits clearly outweigh the short and long-term risks, the use of induction therapy should be avoided. In immunosuppression, as in life, there is no "free lunch." Clinicians need to be certain they fully understand what they are ordering when asking for induction therapy to be administered to their patients.

摘要

20多年来,诱导治疗一直是心脏移植领域争论的焦点。这是一种看似合理的治疗方法,理应比“不进行治疗”更好。然而,对证据的仔细审查却表明并非如此。除了那些受益明显超过短期和长期风险的患者外,应避免使用诱导治疗。在免疫抑制治疗中,就像在生活中一样,没有“免费的午餐”。临床医生在要求对患者进行诱导治疗时,需要确保他们完全清楚自己所开具的治疗方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验